ProPhase Labs, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PRPH | 4544.T | PROGEN.ST | GDR.L | SYNGENE.BO | LH | |
|---|---|---|---|---|---|---|
| Market cap | 93.56K | 217.00B | 15.79M | 15.65M | 166.51B | 29.36B |
| P/E (TTM) | — | 23.5 | — | — | 89.7 | 29.6 |
| Forward P/E | 0.0 | 39.3 | -1.0 | 0.0 | 40.6 | 18.5 |
| Price/book | 0.0 | 1.6 | 0.9 | — | 3.4 | 3.3 |
| Dividend yield | — | 3.22% | — | — | 0.30% | 0.78% |
| 1-year change | −99.66% | −0.56% | −80.24% | −1.91% | −32.81% | +49.12% |
| Today | −7.69% | +3.51% | −3.79% | 0.00% | −0.70% | −1.68% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 20 min.
Latest news
All PRPH news ›ProPhase Labs: Shyam Venkatesan reports 5.48% stake
A single investor reports a passive stake above 5% in ProPhase Labs (PRPH). Stock Titan - [SCHEDULE 13G] ProPhase Labs, Inc. Passive Investment Disclosure (>5%) ProPhase Labs: Shyam Venkatesan reports 5.48% stake The reported position…
Analyzing ProPhase Labs (NASDAQ:PRPH) and Takeda Pharmaceutical (NYSE:TAK)
Posted by Tristan Rich on Oct 6th, 2026 ProPhase Labs (NASDAQ:PRPH – Get Free Report) and Takeda Pharmaceutical (NYSE:TAK – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- stocktitan.net1
- themarketsdaily.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.